Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.4K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

403
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
403
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

220
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
220
Group Design02:01

Group Design

10.3K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using a hand-held pupillometer to quantify pupil constriction as part of the accommodation reflex.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Looking Beyond Dose: Identifying Responders and Non-Responders to RehaCom Computerized Cognitive Rehabilitation in Progressive MS-The CogEx Study.

Neurorehabilitation and neural repair·2026
Same author

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Related Experiment Video

Updated: Jan 23, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.7K

Clinical trials in multiple sclerosis: potential future trial designs.

Navid Manouchehri1, Yinan Zhang1, Amber Salter2

  • 1Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX.

Therapeutic Advances in Neurological Disorders
|June 18, 2019
PubMed
Summary

New genomic and proteomic biomarkers could revolutionize multiple sclerosis (MS) clinical trials. Biomarker validation will enable smaller, faster trials and targeted therapies for MS patients.

Keywords:
Clinical trialDisease Modifying therapyEndophenotypesMultiple SclerosisPharmacologyTrial design

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K

Related Experiment Videos

Last Updated: Jan 23, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.7K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K

Area of Science:

  • Neuroscience
  • Genomics
  • Proteomics

Background:

  • Multiple sclerosis (MS) clinical trials are lengthy and require large sample sizes.
  • Patient heterogeneity and differential responses to disease-modifying therapies (DMTs) complicate trial outcomes.

Purpose of the Study:

  • To propose the use of genomic and proteomic biomarkers to enhance the efficiency of MS clinical trials.
  • To enable smaller sample sizes and faster outcomes through objective molecular measures.

Main Methods:

  • Substitution of current clinical and MRI outcomes with measurable genomic and proteomic biomarkers.
  • Validation of biomarkers for diagnosis, monitoring, prognosis, and treatment response prediction.
  • Subcategorization of MS patients into endophenotypes based on molecular profiles.

Main Results:

  • Biomarkers are currently in early validation phases but show potential for improved trial design.
  • Prospective validation can compare biomarker power against accepted methods.
  • Endophenotype categorization allows for targeted therapy assessment.

Conclusions:

  • Validated biomarkers can homogenize patient populations, minimizing nonresponders in MS trials.
  • This approach facilitates the development of targeted therapies for specific MS endophenotypes.
  • Biomarker-driven trials promise increased efficiency and personalized medicine in multiple sclerosis treatment.